Elevation of cAMP Levels Inhibits Doxorubicin-Induced Apoptosis in Pre- B ALL NALM- 6 Cells Through Induction of BAD Phosphorylation and Inhibition of P53 Accumulation

Fatemi, Ahmad; Kazemi, Ahmad; Kashiri, Meysam; Safa, Majid

Volume 4, Issue 2 (Int J Mol Cell Med 2015) Int J Mol Cell Med 2015, 4(2): 94-102 | Back to browse issues page

Mendeley

Zotero

RefWorks

Fatemi A, Kazemi A, Kashiri M, Safa M. Elevation of cAMP Levels Inhibits Doxorubicin-Induced Apoptosis in Pre- B ALL NALM- 6 Cells Through Induction of BAD Phosphorylation and Inhibition of P53 Accumulation. Int J Mol Cell Med 2015; 4 (2) :94-102
URL: http://ijmcmed.org/article-1-264-en.html

Elevation of cAMP Levels Inhibits Doxorubicin-Induced Apoptosis in Pre- B ALL NALM- 6 Cells Through Induction of BAD Phosphorylation and Inhibition of P53 Accumulation

Ahmad Fatemi¹

, Ahmad Kazemi¹

, Meysam Kashiri¹

, Majid Safa²

1- Department of Hematology, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
2- Department of Hematology, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran. , safa.m@iums.ac.ir

Abstract: (9624 Views)

Recognition of the molecular mechanisms of cAMP action against DNA damage-induced apoptosis can be useful to improve the efficacy of DNA damaging therapeutic agents. Considering the critical role of bcl-2-associated death promoter (BAD) and p53 proteins in DNA damage -induced apoptosis, the aim of this study was to assess the effect of cAMP-elevating agents on these proteins in doxorubicin-treated pre-B acute lymphoblastic leukemia (pre-B ALL) NALM-6 cells.The pre-B ALL cell line NALM-6 was cultured and treated with doxorubicin in combination with or without cAMP-elevating agents forskolin and 3-isobutyl-1-methylxanthine (IBMX). Cell viability was measured by trypan blue staining and MTT assay. For evaluation of apoptosis, annexin-V staining by flow cytometry and caspase-3 activity assay were used. Protein expression of p53, BAD and phoshorylated BAD was detected by western blotting analysis.cAMP-increasing agents diminished the doxorubicin-mediated cytotoxicity in NALM-6 cells as indicated by the viability assays. Annexin-V apoptosis assay showed that the cAMP-elevating agents decreased doxorubicin-induced apoptosis. Moreover, doxorubicin-induced caspase-3 activity was attenuated in the presence of cAMP-increasing agents. Western blot results revealed the reduced expression of p53 protein in cells treated with combination of cAMP-elevating agents and doxorubicin in contrast to cells treated with doxorubicin alone. Expression of total BAD protein was not affected by doxorubicin and cAMP-elevating agents. However, phosphorylation of BAD protein was induced in the presence of cAMP-elevating agents. Our study suggests that elevated cAMP levels inhibit doxorubicin-induced apoptosis in pre-B ALL cells through induction of BAD phosphorylation and abrogation of p53 accumulation.

Keywords: Doxorubicin, Apoptosis, cAMP, p53, BAD

Full-Text [PDF 301 kb] (3635 Downloads)

Type of Study: Original Article | Subject: Cancer
Received: 2014/12/6 | Accepted: 2015/03/16 | Published: 2015/05/22